Drug & intervention
daratumumab
RxCUI 1721947
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
4 shownSystemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeNCT07341867 · 2026-07-30
RECRUITINGAnti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung CancerNCT06015724 · 2024-01-31
ACTIVE_NOT_RECRUITINGNeoadjuvant Listeria or Daratumumab in Prostate CancerNCT03035357 · 2017-03-01
WITHDRAWNA Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung CancerNCT03023423 · 2016-12-23
COMPLETEDConditions being studied
Carcinoma, Non-Small-Cell Lung1Duffy Blood Group, Chemokine Receptor Gene C.-67T>C1Duffy Blood Group, Chemokine Receptor Gene Mutation1Malignant Neoplasms of Male Genital Organs1Multiple Myeloma1Pancreatic Ductal Adenocarcinoma1Prostate Cancer1Refractory Non-Small Cell Lung Cancer1Triple Negative Breast Cancer1
Research locations
Leading sponsors
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.